Summary:
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy
Qualified Participants May Receive:
Patient that qualify will receive free study treatment, laboratories results, Doctor visis and $50.00 per visit completed if qualified.